The Leukemia & Lymphoma Society (LLS), a global organisation involved in the fight against cancer, along with valued partners, has launched its LLS COVID-19 Patient Financial Aid Program to help as many blood cancer patients as possible during the COVID-19 crisis, it was reported on Wednesday.
The program is to commence immediately and will grant USD250 to eligible patients struggling with the economic hardship presented by the pandemic.
The LLS COVID-19 Patient Financial Aid Program is one of many services provided by the LLS for patients, including the The Leukemia & Lymphoma Society Co-Pay Assistance Program, Patient Aid, Susan Lang Pay-It-Forward Patient Travel Assistance Program and Urgent Need Program. It will also offer free clinical trial navigation guidance through LLS's Clinical Trial Service Center, and its Information Resource Center provides patients and families with one-on-one support with a Blood Cancer Information Specialist at 800-955-4572.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis